首页> 外文OA文献 >Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications
【2h】

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

机译:肺部药物输送。第二部分:吸入剂和药物制剂在雾化药物治疗效果中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Research in the area of pulmonary drug delivery has gathered momentum in the last several years, with increased interest in using the lung as a means of delivering drugs systemically. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians and health professionals will have a choice of a wide variety of device and formulation combinations that will target specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. It is now recognized that it is not enough just to have inhalation therapy available for prescribing; physicians and other healthcare providers need a basic understanding of aerosol science, inhaled formulations, delivery devices, and bioequivalence of products to prescribe these therapies optimally.
机译:在过去的几年中,肺部药物输送领域的研究势头迅猛,人们对使用肺部作为系统性输送药物的方式越来越感兴趣。设备技术的进步导致了更高效的输送系统的开发,该系统能够将更大剂量和更细的颗粒输送到肺中。随着更高效的肺部输送设备和复杂配方的问世,医生和卫生专业人员将有多种设备和配方组合的选择,这些组合将针对肺的特定细胞或区域,避免肺部的清除机制并保留在肺内。肺部较长时间。现在已经认识到仅仅提供吸入疗法是不够的。医师和其他医疗保健提供者需要对气溶胶科学,吸入制剂,递送装置和产品的生物等效性有基本的了解,以便以最佳方式开出这些疗法的处方。

著录项

  • 作者

    Labiris, N R; Dolovich, M B;

  • 作者单位
  • 年度 2003
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号